Co-chairs: Prof.dr. Johan Vansteenkiste, UZ Leuven & Prof.dr. Paul Van Houtte, Jules Bordet Institute
19:00 – 22:00hrs.
Immunology in cancer treatment: what can we expect in Lung Cancer?
Dr. Anne-Marie Dingemans, Maastricht UMC+, the Netherlands
Statistics in Immuno-Oncology: what do we need to know?
Mr. Harry Goyvaerts, BMS Group director Biometrics
Optimal management of immune-related adverse events associated with checkpoint point inhibitors in Lung cancer
Dr. Alberto Fusi, Charité UM, Berlin, Germany
Radiation and immunotherapy agents: good partners?
Prof. Dr. Dirk De Ruysscher, UZ Leuven